drugset / Trial / NCT03693391
A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men
Non-randomizedSequentialOpen-labelBasic science
Summary
The purpose of this study is to measure the blocking of \[18F\]JNJ-64511070 binding in the brain at the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination (tmax) of JNJ-64140284 and determine the exposure/receptor interaction of JNJ-64140284 in healthy male participants following single oral dose administration of JNJ-64140284.
Timeline
- Start
- 2018-10-17
- Primary completion
- 2019-03-02
- Completion
- 2019-03-13
Outcome
Outcome not reported
Stopped (Business): “stopped because of a business decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-64140284 | Unknown | 0.5 mg | Oral |
| Subject | JNJ-64140284 | Unknown | 3 mg | Oral |
| Subject | JNJ-64511070 | Diagnostic / imaging agent | 185 mbq | Intravenous |
Indications
No indication recorded.